Karyopharm Therapeutics Inc. (KPTI)

Market Cap	106.09M
Revenue (ttm)	145.67M
Net Income (ttm)	-89.91M
Shares Out	124.68M
EPS (ttm)	-1.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	213,371
Open	0.843
Previous Close	0.854
Day's Range	0.835 - 0.870
52-Week Range	0.617 - 1.950
Beta	0.20
Analysts	Strong Buy
Price Target	5.00 (+487.61%)
Earnings Date	Oct 31, 2024

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2013
• Employees: 325
• Stock Exchange: NASDAQ
• Ticker Symbol: KPTI
• Website: https://www.karyopharm.com

Financial Performance

In 2023, Karyopharm Therapeutics's revenue was $146.03 million, a decrease of -7.03% compared to the previous year's $157.07 million. Losses were -$143.10 million, -13.43% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for KPTI stock is "Strong Buy." The 12-month stock price forecast is $5.0, which is an increase of 487.61% from the latest price.

Price Target

$5.0

(487.61% upside)

Analyst Consensus: Strong Buy